Cargando…
Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients
BACKGROUND: Patients with cancer are at high risk of severe or lethal COVID-19. The impact of SARS-COV-2 vaccination on the risk of developing COVID-19 was investigated in an exhaustive series of patients from a comprehensive cancer center. METHODS: This is a study of the exhaustive population of 23...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828434/ https://www.ncbi.nlm.nih.gov/pubmed/35245864 http://dx.doi.org/10.1016/j.ejca.2022.01.035 |
_version_ | 1784647844494311424 |
---|---|
author | Heudel, Pierre Favier, Bertrand Solodky, Marie-Laure Assaad, Souad Chaumard, Natacha Tredan, Olivier Bachelot, Thomas Ray-Coquard, Isabelle Russias, Bruno Fournier, Marie-Line Mastroianni, Benedicte Avrillon, Virginie Michallet, Anne-Sophie Zrounba, Philippe Chabaud, Sylvie Perol, David Blay, Jean-Yves |
author_facet | Heudel, Pierre Favier, Bertrand Solodky, Marie-Laure Assaad, Souad Chaumard, Natacha Tredan, Olivier Bachelot, Thomas Ray-Coquard, Isabelle Russias, Bruno Fournier, Marie-Line Mastroianni, Benedicte Avrillon, Virginie Michallet, Anne-Sophie Zrounba, Philippe Chabaud, Sylvie Perol, David Blay, Jean-Yves |
author_sort | Heudel, Pierre |
collection | PubMed |
description | BACKGROUND: Patients with cancer are at high risk of severe or lethal COVID-19. The impact of SARS-COV-2 vaccination on the risk of developing COVID-19 was investigated in an exhaustive series of patients from a comprehensive cancer center. METHODS: This is a study of the exhaustive population of 2391 cancer patients who were prescribed SARS-COV-2 vaccination until 09/21. Patient characteristics, documented SARS-COV-2 infection with RT-PCR, and survival were collected. The primary endpoint was the rate of COVID-19 after vaccination. Secondary endpoints included risk factors to develop COVID-19 after vaccination, with a comparison with the cohort of vaccinated health care workers (HCW), and risk factors for death. RESULTS: From January to September 2021, among 2391 patients with cancer under active treatment in whom a SARS-COV-2 vaccine was prescribed, 659 (28%), 1498 (63%) and 139 (6%) received 1, 2, and 3 doses, respectively. Ninety five patients received a single dose of vaccine after a previous COVID-19. Two thousand two hundred eighty five health care workers (HCW) received one (N = 17, 0.7%), 2–3 (N = 2026, 88.7%) vaccine doses and one dose after COVID-19 (N = 242, 10.6%). With a median follow-up of 142 and 199 days for patients and HCW, respectively. Thirty nine (1.6%) patients and 35 (1.5%) HCW developed COVID-19 after vaccination. Six of 39 cancer patients and no HCW died because ofCOVID-19 within 50 days after diagnosis. Independent risk factors for COVID-19 in vaccinated patients were age, single dose of vaccine without previous COVID-19 and anti-CD20 treatment in the last three months. Independent risk factors for death included metastatic disease, gender, cancer type, but also documented COVID-19 before vaccination. CONCLUSIONS: Patients receiving two or more doses of COVID-19 vaccine have reduced risk of COVID-19. The risk of death of vaccinated cancer patients presenting COVID-19 remains high. COVID-19 before vaccination is associated with an increased overall risk of death. |
format | Online Article Text |
id | pubmed-8828434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88284342022-02-10 Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients Heudel, Pierre Favier, Bertrand Solodky, Marie-Laure Assaad, Souad Chaumard, Natacha Tredan, Olivier Bachelot, Thomas Ray-Coquard, Isabelle Russias, Bruno Fournier, Marie-Line Mastroianni, Benedicte Avrillon, Virginie Michallet, Anne-Sophie Zrounba, Philippe Chabaud, Sylvie Perol, David Blay, Jean-Yves Eur J Cancer Original Research BACKGROUND: Patients with cancer are at high risk of severe or lethal COVID-19. The impact of SARS-COV-2 vaccination on the risk of developing COVID-19 was investigated in an exhaustive series of patients from a comprehensive cancer center. METHODS: This is a study of the exhaustive population of 2391 cancer patients who were prescribed SARS-COV-2 vaccination until 09/21. Patient characteristics, documented SARS-COV-2 infection with RT-PCR, and survival were collected. The primary endpoint was the rate of COVID-19 after vaccination. Secondary endpoints included risk factors to develop COVID-19 after vaccination, with a comparison with the cohort of vaccinated health care workers (HCW), and risk factors for death. RESULTS: From January to September 2021, among 2391 patients with cancer under active treatment in whom a SARS-COV-2 vaccine was prescribed, 659 (28%), 1498 (63%) and 139 (6%) received 1, 2, and 3 doses, respectively. Ninety five patients received a single dose of vaccine after a previous COVID-19. Two thousand two hundred eighty five health care workers (HCW) received one (N = 17, 0.7%), 2–3 (N = 2026, 88.7%) vaccine doses and one dose after COVID-19 (N = 242, 10.6%). With a median follow-up of 142 and 199 days for patients and HCW, respectively. Thirty nine (1.6%) patients and 35 (1.5%) HCW developed COVID-19 after vaccination. Six of 39 cancer patients and no HCW died because ofCOVID-19 within 50 days after diagnosis. Independent risk factors for COVID-19 in vaccinated patients were age, single dose of vaccine without previous COVID-19 and anti-CD20 treatment in the last three months. Independent risk factors for death included metastatic disease, gender, cancer type, but also documented COVID-19 before vaccination. CONCLUSIONS: Patients receiving two or more doses of COVID-19 vaccine have reduced risk of COVID-19. The risk of death of vaccinated cancer patients presenting COVID-19 remains high. COVID-19 before vaccination is associated with an increased overall risk of death. Elsevier Ltd. 2022-04 2022-02-10 /pmc/articles/PMC8828434/ /pubmed/35245864 http://dx.doi.org/10.1016/j.ejca.2022.01.035 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Research Heudel, Pierre Favier, Bertrand Solodky, Marie-Laure Assaad, Souad Chaumard, Natacha Tredan, Olivier Bachelot, Thomas Ray-Coquard, Isabelle Russias, Bruno Fournier, Marie-Line Mastroianni, Benedicte Avrillon, Virginie Michallet, Anne-Sophie Zrounba, Philippe Chabaud, Sylvie Perol, David Blay, Jean-Yves Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients |
title | Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients |
title_full | Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients |
title_fullStr | Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients |
title_full_unstemmed | Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients |
title_short | Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients |
title_sort | survival and risk of covid-19 after sars-cov-2 vaccination in a series of 2391 cancer patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828434/ https://www.ncbi.nlm.nih.gov/pubmed/35245864 http://dx.doi.org/10.1016/j.ejca.2022.01.035 |
work_keys_str_mv | AT heudelpierre survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT favierbertrand survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT solodkymarielaure survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT assaadsouad survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT chaumardnatacha survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT tredanolivier survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT bachelotthomas survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT raycoquardisabelle survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT russiasbruno survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT fourniermarieline survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT mastroiannibenedicte survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT avrillonvirginie survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT michalletannesophie survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT zrounbaphilippe survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT chabaudsylvie survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT peroldavid survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients AT blayjeanyves survivalandriskofcovid19aftersarscov2vaccinationinaseriesof2391cancerpatients |